Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

recurrent Breast Cancer

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Locoregional Recurrent Breast Cancer

Broader topic: Breast Cancer

Source population
Not part of this definition
Disease extent
recurrent
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      prior therapy
      status
      stated
    derivation status
    source-attested
    derivation note
    Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
    source wording
    Treatment of Locoregional Recurrent Breast Cancer

    Study evidence for this setting

    16 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT00066690 · Source cited / selected · Scope: unclear

    Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

    4 outcome links · 3 safety-group records · 0 quality-of-life measures

    →

    NCT00074152 · Source cited / selected · Scope: unclear

    Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

    3 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT00408681 · Registry condition search · Scope: unclear

    Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT00602043 · Source cited / selected · Scope: unclear

    F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

    4 outcome links · 1 safety-group records · 1 quality-of-life measures

    →

    NCT00795769 · Registry condition search · Scope: unclear

    Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

    1 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT01037790 · Registry condition search · Scope: unclear

    Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

    1 outcome links · 5 safety-group records · 0 quality-of-life measures

    →

    NCT01120184 · Source cited / selected · Scope: unclear

    A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

    6 outcome links · 3 safety-group records · 8 quality-of-life measures

    →

    NCT01159067 · Registry condition search · Scope: unclear

    Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

    4 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT01806675 · Registry condition search · Scope: unclear

    18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

    5 outcome links · 3 safety-group records · 1 quality-of-life measures

    →

    NCT02246621 · Source cited / selected · Scope: unclear

    A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

    6 outcome links · 2 safety-group records · 5 quality-of-life measures

    →

    NCT02574455 · Source cited / selected · Scope: unclear

    Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

    6 outcome links · 2 safety-group records · 1 quality-of-life measures

    →

    NCT02657889 · Source cited / selected · Scope: unclear

    Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

    6 outcome links · 4 safety-group records · 0 quality-of-life measures

    →

    NCT02819518 · Source cited / selected · Scope: unclear

    Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (

    6 outcome links · 6 safety-group records · 6 quality-of-life measures

    →

    NCT03154190 · Registry condition search · Scope: unclear

    Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT04267575 · Registry condition search · Scope: unclear

    Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

    1 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT04514484 · Registry condition search · Scope: unclear

    Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice